MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, MabDesign’s market analysis gives you an overview of projects in development in the field of infectious diseases.
Infectious diseases are one of the main causes of death in the world, accounting for around 20% of global deaths each year. Tuberculosis, HIV, malaria and antibiotic-resistant bacterial infections in general are among the most deadly infectious diseases. The COVID-19 pandemic also highlighted the threat posed by the emergence of new pathogens, particularly from zoonotic sources.
Faced with these challenges, pharmaceutical research is turning in particular to biotherapies, with more than 3,900 projects currently in the pipeline. The three most targeted indications are viral diseases: COVID-19, HIV and influenza.
Pipeline overview
Zoom on innovative approaches
The pipeline of biomedicines targeting indications in infectious diseases is rich and diverse: it includes both new therapeutic modalities such as microbiotic therapies, advanced therapy drugs and new antibody formats, as well as prophylactic vaccines based on innovative technologies.
Microbiome therapies
Vaccines*
*Excluding ‘historical’ modalities (live attenuated vaccines, inactivated vaccines, subunit vaccines).
Monoclonal antibodies
Cell and gene therapies
This development pipeline, with innovative therapies and next-generation vaccines, represents significant hope in the fight against infectious diseases. These innovations also reflect the growing importance of biotherapies in the global pharmaceutical pipeline, to meet pressing medical needs and prepare for future pandemics.
Want to find out more?
If you’d like to meet industry and academic experts in infectious diseases and find out about the latest innovations in the sector, don’t miss the 8th Immunotherapies and Innovations for Infectious Diseases conference! You can register now, or contact us for more information.
MabDesign has acquired and cultivates its expertise in all market segments associated with biopharmaceuticals and biomanufacturing. Our team of consultants is at your disposal to support you in all your biotherapy-related projects. Feel free to explore our range of services, including our marketing and strategic analyses, if you’d like to find out more!
Sources: MabDesign & GlobalData
Date – November 2024
